Clinical Trials Search at Vanderbilt-Ingram Cancer Center

CTQJ230A - A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease (CVD)

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Linton, MacRae

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

12-29-2021

Trial Type:

Treatment

Protocol ID:

CRE-GEN0001

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available